Screener
Syndax Pharmaceuticals SNDX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 58,845 | 61,636 |
| Selling, general and administrative | 37,588 | 41,031 |
| Collaboration loss | — | 247 |
| Total operating expenses | 99,066 | 103,799 |
| Loss from operations | (34,202) | (83,757) |
| Other (expense) income, net: | ||
| Royalty interest expense | (11,846) | (8,049) |
| Other interest expense | — | (2) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total operating expenses?
- Syndax Pharmaceuticals (SNDX) reported total operating expenses of $99.07M in Q1 2026.
- How has Syndax Pharmaceuticals's total operating expenses changed year-over-year?
- Syndax Pharmaceuticals's total operating expenses decreased by 4.6% year-over-year, from $103.8M to $99.07M.
- What is the long-term trend for Syndax Pharmaceuticals's total operating expenses?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's total operating expenses has grown at a 40.8% compound annual growth rate (CAGR), from $113.49M to $445.68M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Syndax Pharmaceuticals's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude